Simon Henry Schofield Pearce

Simon Henry Schofield Pearce

Auto-generated profile, based on publicly available information

Simon Henry Schofield Pearce

Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in European Thyroid Journal
Verified
Journal Article
Open access
PDF file
GKGeorge Kahaly
George Kahaly
LBLuigi Bartalena
Luigi Bartalena
LHLazlo Hegedüs
Lazlo Hegedüs
LLLaurence Leenhardt
Laurence Leenhardt
KPKris Poppe
Kris Poppe
SPSimon H. Pearce
Simon H. Pearce
Graves’ disease (GD) is a systemic autoimmune disorder characterized by the infiltration of thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R)-expressing tissues. Stimulatory autoantibodies (Ab) in GD activate the TSH-R leading to thyroid hyperplasia and unregulated thyroid hormone production and secretion. Diagnosis of GD is straightforward in a patient with biochemically confirmed thyrotoxicosis, positive TSH-R-Ab, a hypervascular and hypoechoic thyroid gland (ultrasound), and associated orbitopathy. In GD, measurement of TSH-R-Ab is recommended for an accurate diagnosis/differential diagnosis, prior to stopping antithyroid drug (ATD) treatment and during pregnancy. Graves’ hyperthyroidism is treated by decreasing thyroid hormone synthesis with the use of ATD, or by reducing the amount of thyroid tissue with radioactive iodine (RAI) treatment or total thyroidectomy. Patients with newly diagnosed Graves’ hyperthyroidism are usually medically treated for 12–18 months with methimazole (MMI) as the preferred drug. In children with GD, a 24- to 36-month course of MMI is recommended. Patients with persistently high TSH-R-Ab at 12–18 months can continue MMI treatment, repeating the TSH-R-Ab measurement after an additional 12 months, or opt for therapy with RAI or thyroidectomy. Women treated with MMI should be switched to propylthiouracil when planning pregnancy and during the first trimester of pregnancy. If a patient relapses after completing a course of ATD, definitive treatment is recommended; however, continued long-term low-dose MMI can be considered. Thyroidectomy should be performed by an experienced high-volume thyroid surgeon. RAI is contraindicated in Graves’ patients with active/severe orbitopathy, and steroid prophylaxis is warranted in Graves’ patients with mild/active orbitopathy receiving RAI.

26 November 2013 in European Thyroid Journal
Verified
Journal Article
Closed access
PDF file
SPSimon H.S. Pearce
Simon H.S. Pearce
GBGeorg Brabant
Georg Brabant
LDLeonidas Duntas
Leonidas Duntas
Fabio MonzaniFabio Monzani
Fabio Monzani
RPRobin P. Peeters
Robin P. Peeters
JWJean-Louis Wemeau
Jean-Louis Wemeau
Subclinical hypothyroidism (SCH) should be considered in two categories according to the elevation in serum thyroid-stimulating hormone (TSH) level: mildly increased TSH levels (4.0-10.0 mU/l) and more severely increased TSH value (>10 mU/l). An initially raised serum TSH, with FT4 within reference range, should be investigated with a repeat measurement of both serum TSH and FT4, along with thyroid peroxidase antibodies, preferably after a 2- to 3-month interval. Even in the absence of symptoms, replacement therapy with L-thyroxine is recommended for younger patients (10 mU/l. In younger SCH patients (serum TSH <10 mU/l) with symptoms suggestive of hypothyroidism, a trial of L-thyroxine replacement therapy should be considered. For such patients who have been started on L-thyroxine for symptoms attributed to SCH, response to treatment should be reviewed 3 or 4 months after a serum TSH within reference range is reached. If there is no improvement in symptoms, L-thyroxine therapy should generally be stopped. Age-specific local reference ranges for serum TSH should be considered in order to establish a diagnosis of SCH in older people. The oldest old subjects (>80-85 years) with elevated serum TSH ≤10 mU/l should be carefully followed with a wait-and-see strategy, generally avoiding hormonal treatment. If the decision is to treat SCH, then oral L-thyroxine, administered daily, is the treatment of choice. The serum TSH should be re-checked 2 months after starting L-thyroxine therapy, and dosage adjustments made accordingly. The aim for most adults should be to reach a stable serum TSH in the lower half of the reference range (0.4-2.5 mU/l). Once patients with SCH are commenced on L-thyroxine treatment, then serum TSH should be monitored at least annually thereafter.

4 November 2016 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
AJAvais Jabbar
Avais Jabbar
APAlessandro Pingitore
Alessandro Pingitore
SPSimon H. S. Pearce
Simon H. S. Pearce
AZAzfar Zaman
Azfar Zaman
GIGiorgio Iervasi
Giorgio Iervasi
SRSalman Razvi
Salman Razvi

1 February 1996 in Nature
Verified
Journal Article
Closed access
SLSarah E. Lloyd
Sarah E. Lloyd
SPSimon H. S. Pearce
Simon H. S. Pearce
SFSimon E. Fisher
Simon E. Fisher
KSKlaus Steinmeyer
Klaus Steinmeyer
BSBlanche Schwappach
Blanche Schwappach
RTRajesh V. Thakker
Rajesh V. Thakker

1 March 2008 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
LBLuigi Bartalena
Luigi Bartalena
LBLelio Baldeschi
Lelio Baldeschi
ADAlison Dickinson
Alison Dickinson
AEAnja Eckstein
Anja Eckstein
PKPat Kendall-Taylor
Pat Kendall-Taylor
E(European Group on Graves' Orbitopathy (EUGOGO)
European Group on Graves' Orbitopathy (EUGOGO)

10 October 1996 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SPSimon H.S. Pearce
Simon H.S. Pearce
CWCatherine Williamson
Catherine Williamson
OKOlga Kifor
Olga Kifor
MBMei Bai
Mei Bai
MCMalcolm G. Coulthard
Malcolm G. Coulthard
RTRajesh V. Thakker
Rajesh V. Thakker
The calcium-sensing receptor regulates the secretion of parathyroid hormone in response to changes in extracellular calcium concentrations, and mutations that result in a loss of function of the receptor are associated with familial hypocalciuric hypercalcemia. Mutations involving a gain of function have been associated with hypocalcemia in two kindreds. We examined the possibility that the latter type of mutation may result in a phenotype of familial hypocalcemia with hypercalciuria.